Corteva and Inari settle $1.3 billion seed patent dispute mid-trial
Corteva and Inari settled a $1.3 billion seed patent dispute mid-trial. Financial terms were not disclosed, but Inari agreed to destroy Corteva's biological materials. The case was closely watched by the ag-tech industry and the DOJ Antitrust Division.
How this was made
The 30-second read
Why it matters
Resolution removes a major legal cloud, but financial terms remain private, limiting immediate price movement.
Market read
Legal settlement news with moderate relevance for Corteva shareholders; limited broader market impact.
What to watch
Future licensing terms or follow‑on litigation could arise despite the settlement.
Background
The seed‑patent dispute had been closely watched by the ag‑tech industry and regulators.
Ticker impact
Corteva settled a $1.3 billion seed‑patent dispute with Inari, ending the mid‑trial litigation.
potential modest upside as the dispute is resolved
Legal risk is eliminated; no new financial terms disclosed, so impact is limited.
Market effects
Reduces litigation risk in the ag‑tech seed sector.
Minimal effect on U.S. agribusiness markets.
Limited, as the dispute was industry‑specific.
Counterpoint
The settlement may signal deeper IP challenges for Corteva, potentially weighing on the stock.
Key entities
- CompanyCorteva
U.S.-listed agriscience firm (CTVA).
- CompanyInari
Private ag‑tech firm involved in the patent dispute.


